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Abstract
Vitamin D binding protein (DBP)/group-specific component (Gc), correlates positively with serum vitamin D metabolites,
and phenotype influences serum 25-hydroxyvitamin D (S-25(OH)D) concentration. The protein isoform has been associated
with decreased bone mineral density (BMD) and increased fracture risk. We examined the role of GC genotypes in S-25(OH)D
status and BMD in 231 Finnish children and adolescents aged 7219 yr. BMD was measured with DXA from lumbar spine
(LS), total hip, and whole body, and for 175 subjects, radial volumetric BMD was measured with pQCT. Background
characteristic and total dietary intakes of vitamin D and calcium were collected. The concentrations of 25(OH)D, parathyroid
hormone (PTH), calcium and other markers of calcium homeostasis were determined from blood and urine. Genotyping was
based on single-nucleotide polymorphism (rs4588) in the GC gene. The genotype distribution was: GC 1/1 68%, GC 1/2 26%
and GC 2/2 6%. A significant difference emerged in 25(OH)D and PTH concentrations between the genotypes, (p = 0.001 and
0.028 respectively, ANCOVA). There was also a linear trend in: Gc 2/2 had the lowest 25(OH)D and PTH concentrations
(p = 0.025 and 0.012, respectively). Total hip bone mineral content was associated with GC genotype (BMC) (p = 0.05,
ANCOVA) in boys. In regression analysis, after adjusting for relevant covariates, GC genotype was associated with LS BMC
and strength and strain index (SSI) Z-score in both genders, and LS BMD in boys. In conclusion, the present study
demonstrates the association between GC genotypes and S-25(OH)D and PTH concentrations. The results show the
influence of DBP genetic variation on bone mass accrual in adolescence.
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Introduction
Low bone mass during adolescence is a risk factor for the
development of osteoporosis in later stages of life [1]. Vitamin D
deficiency can have a negative effect on bone remodeling and
mineralization [2,3]. Inadequate sun light exposure and nutrition
as well as genetic determinants, such as polymorphism of 7-
dehydrocholesterol reductase, hepatic microsomal enzyme, and
vitamin D binding protein (DBP), also known as group-specific
component (Gc), is associated with vitamin D insufficiency [4].
Serum 25-hydroxyvitamin D [S-25(OH)D] is considered to be the
most reliable marker of vitamin D status. S-25(OH)D concentra-
tions are partly genetically determined [5–7]. A negative
correlation exists between S-25(OH)D and serum parathyroid
hormone (S-PTH) concentration [8]. PTH is a strong regulator of
bone resorption.
For the normal function of vitamin D in the body, most of the
vitamin D and its metabolites in blood are bound to DBP. DBP is
a polymorphic protein and has a structure related to albumin and
the a-fetoprotein gene family [9]. DBP transports 25(OH)D from
the liver to the kidneys and other organs to be further converted to
the biologically most active vitamin D form, 1,25-dihydroxy-
vitamin D [1,25(OH)2D]. DBP binds 85 to 90% of the total
circulating 25(OH)D and 85% of the total circulating 1,25(OH)2D
[10–11]. Vitamin D can also bind to albumin or chylomicrons at
lower levels [12]. There are six common phenotypes of DBP: Gc
1S/1S, Gc 1S/2, Gc 1F/1F, Gc 1S/1F, Gc 1F/2, and Gc 2/2,
which differ according to their amino acid composition and
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glycosylation [13]. Polymorphic DBP differs in its ability to bind
vitamin D metabolites, and the phenotype determines plasma
concentrations of 25(OH)D and 1,25(OH)2D [14–17]. Allele
frequencies of the GC gene vary depending on the ancestral
background [17–18].
In addition to acting as a transport molecule for vitamin D,
DBP has several other important biological roles such as
extracellular actin scavenging, leukocyte C5a-mediated chemo-
taxis, macrophage activation, stimulation of osteoclasts, and
transportation of fatty acids [9,12–13,19]. DBP may impact on
bone in two different ways: through binding and transportation of
vitamin D metabolites and by activating osteoclasts, as DBP-
macrophage activating factor (Gc-MAF) [20]. This factor is
thought to be capable of activating osteoclasts by a cellular
feedback mechanism that downregulates osteoclast activity when
extracellular calcium concentrations increase [21]. Gc-MAF can
also stimulate bone resorption by influencing osteoclast calcium
sensing.
DBP phenotypes are related to bone fracture risk in postmen-
opausal women [22] and GC genotypes to compression strength
index in Caucasian men [23]. Thus, certain phenotypes may be
additional risk factors for vitamin D insufficiency and could
increase the risk of vitamin D insufficiency-related disease by
reducing cell and tissue responses to vitamin D. In addition, the
immunological or other unknown functions of DBP could
independently affect cell and tissue responses [22,24].
The impact of the GC genotype on vitamin D status and bone
mineralization at a young age has received little attention in
research. In this study, we investigated the association between
vitamin D binding protein genotypes (rs4588) and bone health in
children and adolescents. Further, we explored how vitamin D
status and GC genotypes are associated with bone mineral density
(BMD), bone mineral content (BMC), bone structure and the stress
and strain index (SSI). We also show for the first time the
association between GC genotypes and PTH concentrations.
Materials and Methods
Ethics Statement
Ethics Committee approval for this study was obtained at the
Helsinki University Hospital, Helsinki. The participants and their
parents gave an informed written consent before entering the
study.
Study Population
A total of 231 children and adolescents, 160 girls (mean age
1362.5 years) and 71 boys (12.662.7 years), from two different
groups [25,26] were included in this school-based cross-sectional
study in the capital region of Helsinki (60uN), southern Finland.
The subjects were recruited from primary and secondary schools
to cover all age groups. Over 99% of the subjects were Caucasian.
Participants and their parents gave an informed written consent
before entering the study, which was in accord with the Helsinki
Declaration.
Clinical Data
The subjects together with their parents completed a question-
naire on medical and fracture history, medications, overall health,
age at menarche, use of vitamin D and calcium supplements, and
details about their physical activity. The dietary vitamin D and
calcium intakes were evaluated using a food frequency question-
naire covering over 70 foods [3]. Calculations of food nutrient
contents were performed using the Finnish National Food
Composition Database, FineliH (version 2001), which is main-
tained by the National Institute for Health and Welfare. Physical
activity included regular everyday activities (e.g. walking to
school), activity at school, and both guided and unguided
leisure-time activities. A total physical activity score was obtained
by scoring a whole week’s different activities and summing them as
described in detail previously [26]. Forms were checked by the
researchers, and, if needed, information was clarified by interview.
Height (cm) and weight (kg) were measured and compared with
Finnish growth charts. Weight was also expressed as height-
adjusted values, as percentages of the mean in a normal
population of the same sex and height, according to Finnish
standards [27,28].
Based on questionnaire data and serum gonadotrophin and sex
steroid concentrations, pubertal development was scored either as
pre-, mid-, or postpubertal (group 1) by a pediatric endocrinologist
(OM) or according to Tanner stages I–V (group 2). The Tanner
stages were then transformed into pre-, mid-, or postpubertal
categories to obtain a united scale for all subjects. Tanner stages I–
II were considered as prepubertal, stages III and IV midpubertal
and stage V as postpubertal.
Genotype Analysis
Genomic DNA was isolated from EDTA whole-blood or saliva
samples using the Gentra Puregene Kit (Qiagen GmgH, Hilden,
Germany) or WizardH Genomic DNA Purification kit (Promega,
Madison, WI, USA). The The rs4588 and (rs7041) SNPs were
genotyped with RT-PCR (Mx3000P, Stratagene, La Jolla, CA,
USA) using 59GGC AAA GTC TGA GCG CTT GTT A 39 and
59CAG ACT GGC AGA GCG ACT AAA AG 39 primers and
59NEP/TTG CCT GAG GCC ACA CC/NEP-39, 59MAR/TTG
CCT GAT GCC ACA CCC/MAR-39, 59NEP/CCA CAC CCA
AGG AAC TGG C/NEP-39, and 59MAR/CAC ACC CAC
GGA ACT GGC/MAR-39 probes (AllGloTM, Allelogic Biosci-
ences Corporation, Hayward, CA, USA). RT-PCR reactions were
carried out in a 20-mL volume using 75 ng template DNA,
500 nM/primer, 250–500 nM/probe, and 1xBrilliant II QPCR
Master mix (Stratagene, La Jolla, CA, USA). Amplification was
obtained by denaturing at 95uC for 10 min, followed by 55 cycles
of denaturing at 95uC for 30 s, annealing at 60uC for 1 min, and
extension at 72uC for 30 s. The genotyping results were analyzed
by end-point reading in the MxPro software (Mx3000P,
Stratagene, La Jolla, CA, USA). Five percent random samples
were regenotyped to check for genotyping errors.
Biochemistry
Blood samples and second void urine samples were collected at
8–10 am after an overnight fast between November and March
(group 1) or September and March (group 2). S-25(OH)D was
assayed with high-performance liquid chromatography (HPLC,
evaluated Vitamin D External Quality Assessment Scheme,
DEQAS) in the Central Laboratory of Helsinki University Central
Hospital (group 1) or at the Danish Institute for Food and
Veterinary Research (subgroup 2). P2/S- serum intact PTH was
measured with an immunoluminometric method (group 1) or with
a commercial two-site immunoenzymometric assay (group 2)
(IEMA; OCTEIA; IDS, Boldon, UK). Plasma/serum concentra-
tions of calcium (P2/S- Ca), urinary Ca (U-Ca), urinary
phosphorus (U-Pi), and creatinine (U-Crea) were measured using
standard methods.
Bone Densitometry and pQCT
Bone mineral density (BMD), bone mineral content (BMC), and
bone area were measured with DXA (Hologic Discovery A,
pediatric software, version 12.4) from the lumbar spine (LS) (L1–
DBP, 25(OH)D, PTH and Bone Health
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L4), total hip, and whole body (WB). Volumetric BMD and bone
geometry were measured from the non-dominant radius with
pQCT (XCT-2000; Stratec, Pforzheim, Germany) in a group of
175 subjects (104 girls and 71 boys, part of group 1), at the 4% and
66% proximally from the distal end of the non-dominant radius as
described in detail previously [29]. The scans were analyzed using
version 5.50 of the manufacturer’s software package in which the
outer contour of bone is defined with threshold of 280 mg/cm3.
Figure 1. The distribution of GC genotypes and alleles in the study population, and associations among 25(OH)D, PTH and GC
genotypes. (A) Distribution of GC genotypes 1/1, 1/2 and 2/2 among the subjects (N = 159, 61 and 13 respectively). B) Distribution of GC alleles
among the subjects (N = 187 and 44 respectively). (C) Association of GC genotype with S-25(OH)D concentrations. Results are shown for mean (6 SE)
unadjusted values (ANOVA; p= 0.102, N= 158, 59 and 12, respectively) and mean (6 SE) values after adjustment for vitamin D intake, PTH, group 1 or
2, and month when blood sample was taken (ANCOVA; (a) p = 0.001, N = 154, 59 and 12). S-25(OH)D concentration was highest in GC 1/1 and lowest
in GC2/2. A significant difference were present in S-25(OH)D concentrations between GC 1/1 and GC 1/2 (ANCOVA; (b) p = 0.003). There was a negative
linear trend between the genotypes (p = 0.025). (D) Association of GC genotype with PTH concentrations in group 1. Results are shown for mean (6
SE) unadjusted values (ANOVA; p= 0.227, N= 125, 42 and 11 respectively) and mean (6 SE) values after adjustment for calcium intake, S-25(OH)D, and
month when blood sample was taken (ANCOVA; (a), p = 0.028, N= 98, 37 and 8 respectively). PTH levels were highest in GC 1/1 and lowest in GC 2/2
(ANCOVA; (b) p= 0.036). There was a negative linear trend among the genotypes (ANCOVA; p = 0.012).
doi:10.1371/journal.pone.0087292.g001
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The scans were analysed using contour mode 2 (45%) and peel
mode 1 to assess total bone (TB) and trabecular bone (Trab)
parameters at the 4% site. At the 66% site, cortical bone (Cort)
was detected with separation mode 1 and a threshold of 710 mg/
cm3. Also BMC, total bone (TB), cross-sectional area (CSA), and
SSI were calculated. Measured values were transformed into Z-
scores using equipment-specific age- and sex-adjusted reference
data for US Caucasian children in DXA, and in pQCT according
to Rauch et al. [30–31].
Statistical Analysis
Descriptive data are reported as means 6 SD. We used a Chi-
square test to assess whether DBP genotype distributions were in
Hardy–Weinberg equilibrium. Association of variables was tested
with Pearson correlation. Logarithmic transformation was applied
to non-Gaussian variables. If outliers were detected, Spearman
correlation was used instead. Partial correlation was used to
illustrate the association after controlling for confounding factor(s).
Associations between GC genotype, S-25(OH)D and PTH were
analyzed with analysis of covariance (ANCOVA), with relevant
covariates (shown in Fig. 1C and 1D legend texts, respectively). Test
for linear trend was performed by using contrast analysis. Before
multiple linear regression analysis, several variables were log-
transformed to obtain normal distribution (e.g. PTH). Simple
regression analysis in the whole study population was first
performed to screen potential predictors for BMC, BMD, and a
group of 181 subjects (110 girls and 71 boys, group 1) for SSI, and
a multivariate linear regression model was used to identify and
determine significant predictors for bone mineral content, mass,
and SSI. In regression analysis, GC genotype was used as a dummy
variable [grouped into 0 (GC 1/1) and 1 (GC 1/2, GC 2/2)]. All
calculations were performed using PASW 18.0 for Windows. A p-
value equal to or less than 0.05 was considered significant.
Results
Genotype and Allele Distributions
We identified six different GC diplotypes : 1S/1S, 1S/2, 1F/1F,
1F/2, 1S/1F, and 2/2. Allele frequencies are shown in Fig. 1B.
Because of the small number of subjects in some of the diplotypes,
we used only the data of rs4588 genotypes, GC 1/1, GC 1/2 and
GC 2/2 in this study. The most common GC genotype was 1/1
(68%) and the rarest 2/2 (6%) (Fig. 1A). The allele frequency for
allele 1 was 81% and for allele 2 19%. The distributions of the
rs4588 GC genotypes were in compliance with Hardy–Weinberg
equilibrium (p = 1.000). The genotypes were equally distributed in
both groups.
Characteristics of Subjects
The background characteristics of the subjects are presented in
table 1. Relative weight (height-adjusted weight) was above 20%
( = overweight) in 31 subjects (15%) and above 40% ( = obesity) in
7 subjects (3%).
In girls, were 33% prepubertal, 31% pubertal and, 36%
postpubertal. In boys, the corresponding distributions were 52%,
16% and 32%.The mean total intakes of calcium and vitamin D
were in line with recommendations [32] in both genders. The
mean vitamin D intakes were 8.3 mg and 11.3 mg in girls and boys,
respectively. No significant difference in vitamin D intake was
present between the genotypes in both genders. We observed that
67% of the study population had S-25(OH)D concentration below
50 nmol/L (68% of girls, 69% of boys). The participants were
physically active: 59% had a physical activity score .14 and 9%
.18, indicating more than 1.5 and 2 hours, respectively, of
physical activity daily.
Table 1. Baseline characteristics by sex and Gc genotype the comparison are made by ANOVA without covariates.
Girls Boys
Genotype GC 1/1 GC 1/2 GC 2/2 P-value GC 1/1 GC 1/2 GC 2/2 P-value
N= 105 N= 46 N= 9 N=54 N= 15 N= 4
Age (year) 12.962.3 13.062.6 14.363.9 0.258 12.6162.7 12.6362.2 12.664.8 0.999
Height (cm) 154.8611.2 154.3610.9 153.0612.5 0.881 154.8617.6 155.8617.4 157.7629.4 0.946
Weight (kg) 46.3612.3 47.1612.2 42.9610.9 0.637 48.9618.7 48.6618.2 45.3622.3 0.931
Weight (%) 4.66617 7.95615.6 21.1169.0 0.267 8.17614.5 9628.1 27.3360.6 0.345
Pubertal stage
prepubertal 34 15 4 0.798 27 9 2 0.608
pubertal 35 15 0 9 3 0
postpubertal 36 16 5 18 3 2
Vitamin D intake (mg/day) 8.364.7 8.165.6 9.766.9 0.739 11.165.4 12.965.7 8.362.0 0.427
Ca intake (mg/day) 14866622 13286597 12666509 0.239 16026528 16386456 9556125 0.206
S-25(OH)D (nmol/L) 46.0615.4 42.3612.4 38.569.0 0.153 45.1612.8 40.769.5 45.368.0 0.459
S2/P-PTH (ng/L) 43.9622.4 39.1613.0 32.068.5 0.124 41.6624.2 45.9617.8 40618.3 0.790
S2/P-Ca (mmol/L) 2.4060.17 2.4460.20 2.3560.12 0.316 2.3460.09 2.3160.09 2.360.03 0.373
S/P-Pi (mmol/L) 1.3760.18 1.3860.19 1.2960.14 0.434 1.4260.22 1.5560.12 1.4560.07 0.090
U-Ca/UCrea (mmol/mmol) 0.2160.18 0.2060.2 0.1260.06 0.510 0.1960.16 0.2560.23 0.2260.15 0.467
U-Pi/UCrea (mmol/mmol) 1.5560.72 1.5660.74 1.5460.47 0.989 2.1962.7 1.9160.99 2.360.53 0.908
Physical activity score 16.564.1 15.963.8 13.764.3 0.202 14.863.6 15.464.1 14.562.3 0.870
Mean 6 SD, N in parentheses.
doi:10.1371/journal.pone.0087292.t001
DBP, 25(OH)D, PTH and Bone Health
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e87292
GC Genotype and S-25(OH)D and PTH Concentrations
A significant negative correlation existed between S-25(OH)D
and month of sampling, the concentrations being higher in late
autumn than in early spring (r =20.184, p = 0.005) and between
S-25(OH)D and PTH (r = 20.166, p = 0.022) after controlling for
calcium intake. A significant difference was present in S-25(OH)D
concentrations among the genotypes, the mean concentration
being highest in GC 1/1 and lowest in GC 2/2 (p = 0.001,
ANCOVA) after adjusting for relevant covariates (vitamin D
intake, PTH, group 1 or 2, and month of sampling) (Fig. 1 C).
When pairwise comparisons were made, only the difference
between GC 1/1 and GC 1/2 was significant (p = 0.003). However,
there was a negative linear trend (p for trend = 0.025) among the
genotypes. The relationship between genotypes and PTH was
analysed only in group 1 to avoid the bias of the PTH assays in the
two groups. The mean PTH concentrations differed among the
genotypes; individuals with GC 1/1, who had on average the
highest S-25(OH)D concentration, also had the highest PTH
concentration, individuals with GC 1/2, who had on average the
intermediate S-25(OH)D concentration, also had intermediate
PTH concentration, and individuals with GC 2/2, who had on
average the lowest S-25(OH)D concentration, also had the lowest
PTH concentration (p = 0.028, linear trend p = 0.012), covariates:
calcium intake, S-25(OH)D, and month of sampling (Fig. 1D).
After removing S-25(OH)D from covariates, the association
between GC genotype and PTH remained partly significant
(p = 0.072 and linear trend p = 0.026).
Associations between Bone Variables and GC Genotype
A significant difference emerged between boys and girls in
BMD measured with DXA (ANCOVA, covariates: age, height,
weight, S-25(OH)D, puberty, and exercise). Boys had a larger total
hip area (p = 0.012), BMC (p,0.001), and BMD (p,0.001). Girls
had larger WB BMD (p = 0.035). Also in volumetric BMD
Table 2. Bone variables for genotype 1/1 and genotypes Gc
1/2 and 2/2 combined in the whole study population
measured with DXA.
Genotype GC 1/1 GC 1/2 and 2/2 Pa
Pb
N 158a 73a
123b 59b
LS area (cm2) 47.569.8a 46.669.8a 0.495a
45.769.2b 45.869.8b 0.940
LS BMC (g) 38.5614.8a 37.4615.1a 0.576a
36.2614.0b 36.1615.0b 0.993b
LS BMD (g/cm2) 0.7860.16a 0.7760.16a 0.675a
0.7660.16b 0.7660.17b 0.988b
LS BMD Z 0.1360.98a 20.0960.93a 0.110a
0.1260.98b 0.0160.95b 0.384b
Total hip area (cm2) 29.265.7a 28.465.6a 0.336a
28.164.9b 28.065.6b 0.685b
Total hip BMC (g) 24.567.8a 23.567.7a 0.369a
23.066.9b 22.967.6b 0.855b
Total hip BMD (g/cm2) 0.8260.12a 0.8160.14a 0.540a
0.8160.12b 0.8160.14b 0.964b
Total hip BMD Z 0.2260.89a 0.1660.9a 0.619a
0.2760.92b 0.2360.9b 0.763b
WB area (cm2) 21406376a 21146370a 0.674a
20666370b 20606368b 0.651b
WB BMC (g) 18036508a 17706500a 0.681a
17016491b 17006504b 0.985b
WB BMD (g/cm2) 0.8360.10a 0.82260.11a 0.714a
0.8160.10b 0.8160.11b 0.945b
WB Z 0.08660.83a 20.08560.75a 0.196a
0.02460.82b 0.10960.73b 0.499b
Values are presented as mean 6 SD. ANOVA (a) and ANCOVA (b). ANCOVA
covariates: Sex and age (except for the Z-score), height, weight, S-25OHD,
puberty and physical activity score. LS = lumbar spine, WB =whole body,
BMC=bone mineral content, BMD= bone mineral density, Z = age and sex
adjusted value (Z-score).
doi:10.1371/journal.pone.0087292.t002
Table 3. Bone variables for genotype 1/1 and genotypes Gc
1/2 and 2/2 combined in girls measured with DXA.
Girls
Genotype GC 1/1 GC 1/2 and 2/2 Pa
N 105a 55a Pb
84b 44b
LS area (cm2) 46.968.8a 46.969.3a 0.959a
45.668.2b 46.369.5b 0.363b
LS BMC (g) 38.2613.3a 38.6614.9a 0.876a
36.4612.5b 37.5615.4b 0.282b
LS BMD (g/cm2) 0.7960.15a 0.8060.16a 0.801a
0.7760.15b 0.78560.17b 0.406b
LS BMD Z 20.00360.98a 20.0561.01a 0.762a
0.02361.04b 0.00761.04b 0.923b
Total hip area, (cm2) 28.464.1a 28.164.5a 0.698a
27.863.6b 28.164.6b 0.427b
Total hip BMC (g) 23.165.6a 23.166.7a 0.947a
22.465.1b 22.966.9b 0.321b
Total hip BMD
(g/cm2)
0.8160.11a 0.81060.14a 0.894a
0.8060.109b 0.80360.147b 0.730b
Total hip BMD Z 0.2360.9a 0.19160.96a 0.809a
0.2960.96b 0.25260.94b 0.818b
N 75a 35a
57b 29b
WB a (cm2) 21476320a 21436341a 0.951a
20936321b 20956344b 0.888b
WB BMC (g) 17916421a 18316478a 0.652a
17226422b 17636499b 0.152b
WB BMD (g/cm2) 0.8260.09a 0.8460.11a 0.361a
0.8160.09b 0.8360.12b 0.130b
WB BMD Z 20.02060.79a 0.00660.8a 0.881a
20.04260.83b 0.12060.75b 0.351b
Values are presented as mean 6 SD. ANOVA (a) and ANCOVA (b). ANCOVA
covariates: age (except for the Z-score), height, weight, S-25OHD, puberty and
physical activity score. LS = lumbar spine, WB =whole body, BMC=bone
mineral content, BMD= bone mineral density, Z = age and sex adjusted value
(Z-score).
doi:10.1371/journal.pone.0087292.t003
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measured with pQCT, boys had a higher BMC in distal and
proximal radius (p,0.001 and 0.001, respectively), higher SSI
(p,0.001), and larger total bone area in distal and proximal sites
(p = 0.006 and p = 0.000, respectively). Boys also had higher
cortical BMD (p = 0.001).
BMD values based on DXA measurements between genotypes
GC 1 and the combined genotypes GC 1/2 and 2/2 are presented
in table 2, 3 and 4 (ANOVA and ANCOVA). After adjusting for
relevant covariates (age, sex, weight, height, S-25(OH)D, pubertal
stage, and physical activity), a significant difference emerged in
total hip BMC between genotypes in boys (p = 0.05) (Table 4).
Regression Analysis of BMC, BMD, and SSI
To determine the factors associated with LS, total hip, and WB
BMC, BMD Z-scores, and SSI Z-scores in children and
adolescents, multiple linear regression analyses were performed.
In these regression models, age, height, weight, GC genotype, S-
25(OH)D and PTH concentrations, physical activity, and pubertal
stage were included (Tables 5 and 6). The regression model
accounted for 81–87% of the variance (adjusted R2) in LS BMC,
82% of the variance in total hip BMC, 75–87% of the variance in
WB BMC (Table 5), 16–26% of the variance in LS BMD Z-score,
9–24% of the variance in total hip BMD, 14–19% of the variance
in WB BMD Z-score, and 8–26 of the variance in SSI Z-score
(Table 6). Among all the independent variables; weight, age,
pubertal stage and GC genotype were the significant determinants
of LS BMC in both genders, and in addition height was a
significant determinant of LS BMC in girls (Table 5).
In the regression model for LS BMC, the GC genotype variable
was a significant determinant in both genders (p = 0.030,
p = 0.049, Table 5). Weight, pubertal stage and age in boys, and
height, S-25(OH)D concentration, pubertal stage, age and GC
genotype in girls, were significant determinants of total hip BMC.
Weight, pubertal stage, and age in boys and weight, pubertal stage,
S-25(OH)D concentration and age in girls determined WB BMC
(Table 5). Determinants for LS BMD Z-score were height and
weight in girls and weight and GC genotype in boys; whereas
height and weight in girls and weight in boys were the significant
determinants for total hip BMD Z-scores.
Height and S-25(OH)D concentration in girls and physical
activity in boys were the significant determinants of WB BMD Z-
score. In addition GC genotype was almost a significant
determinant for WB BMD Z-score in boys (p = 0.053). Weight,
S-25(OH)D concentration, GC genotype and PTH in girls
determined SSI. In boys, no significant regression model was
found for SSI (N = 42, p = 0.187, Table 6). Because of this,
regression analysis was also performed in the total study
population with the same determinants as in Table 6; in this
regression model, weight (p = 0.005), S-25(OH)D concentration
(p = 0.013), GC genotype (3.1% of the variance, p = 0.015), and
physical activity (p = 0.001) were significant determinants of SSI Z-
score.
Discussion
We have studied for the first time vitamin D binding protein
polymorphism among healthy school-children and adolescents in
Finland. We found that the genotypes were in Hardy and
Weinberg equilibrium and that the distribution differed from the
Dutch and Danish populations. In our study population, the
frequency of the rare GC 2 allele was 19%, in the Dutch
population 27% [33], and in the Danish population 26% [14].
The special genetic origin and long isolation of Finns may explain
the different frequencies of alleles relative to other European
countries [18,34–35].
Our study revealed a significant difference in 25(OH)D
concentrations among the GC genotypes in children and
adolescents. This finding is in line with several other studies
[4,33,36–39]. We observed that the S-25(OH)D concentrations
were highest in subjects who had genotype GC 1/1, intermediate
in GC 1/2 and lowest in GC 2/2. Similar finding has been shown
in other studies [9,15]. It has been proposed that the Gc2 protein
has significantly lower affinity to 25(OH)D compared to Gc1S and
Gc1F proteins [16]. Lauridsen [15] showed that plasma concen-
tration of DBP was significantly higher in phenotype 1/1,
intermediate in 1/2 and lowest in 2/2.They speculated that the
observed difference could be due to different characteristics of the
Gc phenotypes. We did not measure the DBP concentrations in
the present study.
The relationship between genotypes and PTH was analysed
only in group 1 to avoid the bias of the two assays. PTH
concentration correlated negatively with S-25(OH)D and similar
finding was present in the whole population. This correlation has
Table 4. Bone variables for genotype 1/1 and genotypes Gc
1/2 and 2/2 combined in boys measured with DXA.
Boys
Genotype GC 1/1 GC 1/2 and 2/2 Pa
N 53a 18a Pb
39b 15b
LS area (cm2) 48.6611.6a 45.6611.3a 0.344a
46.1611.3b 44.3611.0b 0.212b
LS BMC (g) 39.2617.4a 33.7615.7a 0.239a
35.5616.8b 32.2615.8b 0.102b
LS BMD (g/cm2) 0.7760.17a 0.7160.15a 0.158a
0.7460.16b 0.7060.15b 0.100b
LS BMD Z 0.39160.92a 20.200667a 0.014a
0.35860.81b 20.0760.66b 0.067b
Total hip area, (cm2) 30.767.78a 29.268.4a 0.506a
28.767.0b 27.468.1b 0.087b
Total hip BMC (g) 27.1610.5a 24.7610.4a 0.412a
24.569.6b 22.669.7b 0.050b
Total hip BMD (g/cm2) 0.8660.14a 0.8260.13a 0.355a
0.8360.13b 0.8060.12b 0.295b
Total hip BMD Z 0.2160.87a 0.0660.68a 0.510a
0.2860.83b 0.0860.74b 0.420b
WB a (cm2) 21306447a 20606425a 0.554a
20256431b 19996422b 0.327b
WB BMC (g) 18206614a 16486527a 0.290a
16686580b 15826518b 0.070b
WB BMD (g/cm2) 0.83560.123a 0.78460.10a 0.117a
0.80660.12b 0.77660.09b 0.088b
WB BMD Z 0.2360.87a 20.2660.62a 0.029a
0.20960.78b 20.14460.66b 0.111b
Values are presented as mean 6 SD. ANOVA (a) and ANCOVA (b). ANCOVA
covariates: age (except for the Z-score), height, weight, S-25OHD, puberty and
physical activity score. LS = lumbar spine, WB=whole body, BMC=bone
mineral content, BMD= bone mineral density, Z = age and sex adjusted value
(Z-score).
doi:10.1371/journal.pone.0087292.t004
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been shown in many studies [8]. Interestingly, however, within the
genotype groups, GC 2/2, with the lowest 25(OH)D concentra-
tions, also had the lowest PTH concentration, and GC 1/1, with
the highest 25(OH)D concentrations, had the highest PTH
concentration (group 1). Taes et al. [40] have noted a similar
association between DBP phenotype and S- PTH concentrations
in elderly men, but this finding was not statistically significant. In
addition, it is noteworthy that within the genotypes an inverse
correlation existed between PTH and 25(OH)D. The distribution
of the subjects from the different groups was similar in all GC
groups. Hence, some mechanism associated with GC could
underlie these results.
Only a few studies have investigated vitamin D binding protein
polymorphism and bone health [22–23,33,41–43]. To the best of
our knowledge, this study is the first to evaluate the association
between GC genotype and bone health in children and adoles-
cents. One strength of our study is the extensive background
characteristic data we have collected, i.e. sunshine exposure,
dietary intakes of vitamin D and calcium as well as intake from
supplements and physical activity, which enables the use of more
specific covariates and increases the power of statistical analysis.
We showed that total hip BMC was lower in the combined Gc 1/2
and Gc 2/2 genotype in boys. In regression models, LS BMD Z-
scores (p = 0.039) and WB BMD Z-scores (p = 0.053) were
associated with GC genotype in boys. In girls, by contrast, we
detected no association between GC genotype and BMD. Papiha
et al. [43] have reported a relationship between GC gene
(TAAA)(n)-Alu polymorphism and spinal as well as total hip
BMD in men. In addition, DBP polymorphism has been shown to
be associated with BMD and the fracture risk in men [42]. In a
study on Japanese postmenopausal women, SNPs linkage disequi-
librium with DBP was associated with radial BMD [41]. Lauridsen
et al. [22] found no significant difference in BMD in postmeno-
pausal women among Gc phenotypes. Giroux et al. [44] evaluated
the association of 23 candidate genes with high-density polymor-
phisms with BMD in premenopausal Canadian women. The genes
studied were involved in calcium and vitamin D regulation or
associated with estrogen metabolism and bone. One of the genes
studied was the DBP coding gene, but no association was found
with BMD. However, genes involved in the biosynthesis of vitamin
D (CYP2R1 and CYP27A1) were associated with BMD.
In our study, an association existed between GC genotype and a
marker of bone strength, SSI [45]. Low SSI, vBMD, cortical area
and aBMD have been reported to associate with increased fracture
risk in children [46]. Previous findings in adults have reported an
association between DBP haplotype and fracture risk, especially
when dietary calcium intake was low [33]. In our study
population, the mean calcium intake was high, but we nevertheless
found a similar association between genotype and SSI. Xu et al.
[23] established an association between compression strength
index (CSI) and DBP polymorphism in Caucasian men. Lauridsen
et al. [22] observed a difference in the fracture risk between
genotypes in postmenopausal women; the risk was highest in GC
1/1, intermediate in GC 1/2, and lowest in GC 2/2. In our study,
the SSI was lowest in GC2/2, intermediate in GC 1/1 and highest
in GC 1/2. These results resemble previous findings on the
association of GC gene polymorphism and bone [22–23,33], but
the number of subjects in our study was low and no firm
conclusions can be drawn. However, when the heterozygote and
GC 2/2 groups were combined in regression analysis, the group
size was larger and a similar association was noted. These findings
may illustrate a difference in the genetic effect of DBP between
young developing bone and the elderly skeleton. The rs4588 (and
rs7041) polymorphism, which we studied, is in exon 11 (domain
Table 5. Linear regression analysis for determinants of bone mineral content in groups defined by sex.
LSBMC Total hip BMC WB BMC
r2 ß P r2 ß P r2 ß P
Girls (N = 159)
Regression model 0.873 #0.001 0.824 #0.001 0.748 #0.001
Height (cm) 0.003 0.124 0.021 0.131 0.248 #0.001 0.006 0.934
Weight (kg) 0.015 0.111 0.016 0.044 0.417 0.578 0.475 #0.001
Pubertal stage 0.005 20.082 0.014 0.011 20.126 0.001 0.067 0.201 #0.001
S- 25(OH)D (nmol/L) 0.629 0.522 #0.001 0.655 0.565 #0.001 0.005 20.116 0.031
GC genotype* 0.003 0.065 0.030 0.017 0.105 0.003 20.062 0.144
Exercise (physical activity score) 20.033 0.255 20.024 0.480 0.020 0.627
Age 0.218 0.357 #0.001 0.010 0.179 0.002 0.098 0.496 #0.001
Boys (N = 73)
Regression model 0.812 #0.001 0.824 #0.001 0.873 #0.001
Height (cm) 0.001 0.997 0.045 0.228 #0.001 0.073 0.563
Weight (kg) 0.030 0.269 0.017 0.014 0.228 0.032 0.061 0.382 #0.001
Pubertal stage 0.031 0.297 0.003 0.015 0.249 0.008 0.019 0.188 0.020
S-25(OH)D (nmol/L) 0.007 0.894 0.069 0.191 0.084 0.066
GC genotype* 0.010 20.019 0.049 20.073 0.161 0.008 20.093 0.041
Exercise (physical activity score) 20.015 0.807 20.742 0.461 20.003 0.954
Age 0.741 0.416 0.002 0.750 0.287 0.019 0.785 0.394 #0.001
r2 values are adjusted and ß values are standardized. BMC=bone mineral content, LS = lumbar spine, WB= whole body.
*GC genotype is used as a dummy variable.
doi:10.1371/journal.pone.0087292.t005
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III), an area responsible for non-sterol activities together with
domain II and also the macrophage/osteoclast activation of DBP
[33]. The difference in bone fractures has been proposed to be due
to Gc-MAF formation [22]. In individuals with genotype GC 1/1,
the concentration of DBP is higher, and therefore, there is more
substrate for Gc-MAF formation. Furthermore, the rate of
osteoclast formation is higher. Another reason could be differences
in glycosylation of DBP protein between the genotypes because the
formation of Gc-MAF requires the removal of glucose residuals.
We found that PTH concentrations were higher in those
genotype groups where 25(OH)D was also higher. Lauridsen et al.
[15] found no difference in PTH between the genotype groups,
although the genotypes differed in 25(OH)D concentrations. In
some studies concerning DBP, PTH has not been measured.
Carpenter et al. [17] observed no effect of GC genotype on the
relationship with 25(OH)D and PTH, but did not study the
relationship among GC genotype and PTH. It has been shown that
vitamin D prohormones directly suppress the secretion of PTH
from the parathyroid glands, and this suppression requires the
vitamin D receptor [47]. According to our results, PTH was low in
genotype 2/2, in which the S-25(OH)D concentration was also
low. We hypothesize that in this case the amount of free (unbound)
25(OH)D and 1,25(OH)D is higher in genotype 2/2, and thus,
there are more free forms available to suppress PTH secretion
from the glands. Powe et al. [48] hypothesized that circulating
DBP is an inhibitor of the biological action of vitamin D in
humans. The inverse relationship that we discovered between GC
genotypes and BMD could be caused by the difference in free or
bound serum DBP levels among different genotypes, which can
lead to differences in the inhibition of vitamin D action and in
osteoclast function by Gc-MAF activation.
A weakness of our study is the limited number of subjects,
especially in the rarest genotype GC 2/2, and the small number of
boys. Another limitation is that the data consist of two groups.
Because of the low frequency of the rarest genotype, it was not
possible to divide subjects into groups according to puberty. In
girls, the distribution was quite even, but only 16% of the boys
were pubertal. When the subjects were grouped according puberty
and genotype, girls had fairly even group sizes, except for the GC
2/2 group, where girls were either prepubertal or postpubertal and
none were in puberty. Boys had no pubertal subjects in the
genotype group GC 2/2. However, when the genotypes GC 1/2
and 2/2 were combined in the analyses, the distribution into
puberty groups was more even. The observational design of our
study prevented us from establishing a causal relationship between
GC genotype, S-25(OH)D, PTH and bone accrual in adolescence.
Conclusion
This is the first study to examine the association between GC
genotype on bone health in children and adolescents. These results
suggest that S-25(OH)D and PTH concentrations differ among GC
genotypes and that variation exists in BMD and bone strength
index among genotypes. Variation in S-25(OH)D among geno-
types suggests differences in vitamin D utilization. BMD variables
among the genotypes differed only in boys. This may be due to
gender differences in the phase of skeletal development. We
conclude that DBP may be one factor affecting bone mass accrual
during adolescence. In the future, DBP could be useful in detecting
Table 6. Linear regression analysis for determinants of lumbar spine, total hip and whole body BMD and strength strain index Z-
score in groups defined by sex.
LS BMD (Z-score) Total hip BMD (Z-score) WB (Z-score) SSI (Z-score)
r2 ß P r2 ß P r2 ß P r2 ß P
Girls (N = 159) (N = 73)
Regression model 0.260 #0.001 0.237 #0.001 0.143 0.003 0.265 #0.001
Height (cm) 0.097 20.503 #0.001 0.232 20.654 #0.001 0.064 20.506 0.002 20.668 0.060
Weight (kg) 0.163 0.797 #0.001 0.005 0.739 #0.001 0.245 0.110 0.104 0.525 0.003
Pubertal stage 0.080 0.276 0.066 0.413 0.093 0.407 0.241 0.060
S-25(OH)D (nmol/L) 0.025 0.769 20.906 0.339 0.079 0.451 #0.001 0.051 20.529 0.010
GC genotype* 20.077 0.276 20.050 0.482 20.046 0.645 0.028 20.272 0.011
Exercise (physical activity
score)
0.037 0.532 0.073 0.303 0.010 0.921 0.424 0.086
PTH 0.082 0.603 0.005
Boys (N= 73) N= 56 N=73 N= 42
Regression model 0.162 0.018 0.090 0.015 0.195 0.015 0.082 0.187
Height (cm) 0.039 20.540 0.042 20.478 0.198 20.023 0.940 20.728 0.124
Weight (kg) 0.056 0.659 0.006 0.090 4.474 0.006 20.113 0.663 0.654 0.097
Pubertal stage 0.001 0.991 20.191 0.477 0.102 0.616 0.067 0.536 0.043
S-25(OH)D (nmol/L) 20.017 0.885 0.081 0.564 0.219 0.067 20.008 0.962
GC genotype* 0.067 20.243 0.039 20.138 0.335 0.049 20.252 0.053 0.004 0.982
Exercise (physical activity
score)
0.001 0.991 0.091 0.584 0.146 0.356 0.023 0.015 0.431 0.018
PTH 20.033 0.833
r2 values are adjusted and ß values are standardized. PTH was included in SSI model. BMD=bone mineral density, LS = lumbar spine, WB= whole body, SSI = strength
strain index, * GC genotype is used as a dummy variable.
doi:10.1371/journal.pone.0087292.t006
DBP, 25(OH)D, PTH and Bone Health
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e87292
individuals who are more susceptible to vitamin D deficiency,
especially while their skeleton is still developing.
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